



THE  
**ART** *and* **SCIENCE**  
of Managing the New Melanoma Landscape

**5th Annual Collaborative Conference**

**Friday, September 28 -  
Saturday, September 29, 2018**

Houston Marriott Medical Center

6580 Fannin Street

Houston, Texas

THE UNIVERSITY OF TEXAS

**MD Anderson**  
**Cancer Center**

Making Cancer History®




## Focus

The diagnosis, prognosis, and management of patients with melanoma is evolving rapidly due to new understanding, guidelines, and regulatory approvals. Due to these changes, there are many areas of need for physician education in order to optimize the care of patients with this disease. Thus, this educational activity will reach clinicians in both the academic and community clinical settings to raise the level of knowledge about current and emerging treatment options for patients with melanoma.

The University of Texas MD Anderson Cancer Center will develop a high-quality educational activity that is designed to overcome barriers to optimized patient care in the rapidly changing landscape of melanoma. MD Anderson has selected this live event, which will be multi-topic and multi-supported, as the foundation for an educational initiative that will provide an environment conducive to engagement and dialogue with peers and presenters. The initiative is anticipated to increase understanding and competency through expert presentations and related panel discussion on representative clinical cases.

Through lectures, case presentations and panel discussions, this activity is designed to meet the continuing medical education needs of medical oncologists, dermatologists, surgical oncologists, dermatopathologists, scientists and all other healthcare providers managing patients with melanoma.



## Educational Objectives

After attending the conference, participants should be able to:

- Utilize the latest criteria and clinical evidence for treatment options for melanoma patients with clinically localized disease and interpret the components of the updated AJCC staging system for melanoma (*Knowledge, Competence, Performance, Patient Outcomes*);
- Make evidence-based decisions about the use of adjuvant immune and targeted therapies in patients with surgically resected stage III disease (*Knowledge, Competence*);
- Make evidence-based decisions about the optimal selection and use of immunotherapy in the first-line setting in patients with metastatic disease (*Knowledge, Competence*);
- Make evidence-based decisions about the optimal selection and use of targeted therapies in patients with BRAF-mutant metastatic disease (*Knowledge, Competence*);
- Diagnose and treat toxicities from current systemic therapies for advanced melanoma patients (*Knowledge, Competence, Performance*);
- Understand the current data about the role of different treatment modalities, including immune and targeted therapies, in patients with brain metastases and with non-cutaneous melanomas (*Knowledge*).

## Educational Methods

Lecture/Didactic • Case Study • Audience Response System • Panel Discussion

## Target Audience

This conference should be of value to medical oncologists, surgical oncologists, dermatologists, nurse practitioners, scientists/researchers and other healthcare providers managing patients with melanoma.

## Evaluation

A conference evaluation link will be included in the final program. This online survey will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

## Accreditation/Credit Designation

### Physicians

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 11.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## CME Certificates and Attendance Verification Certificates

Certificates awarding *AMA PRA Category 1 Credits™* or certificates documenting attendance will be emailed when an individual completes the online CME Verification process.

## Physician Payments-Sunshine Act

MD Anderson complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.

## Presentations

All of the PowerPoint presentations will be posted online after the conference. You will receive an invitation email from **Study@MD Anderson** to create a username and password to log into Study. If you do not receive this instructional email by October 5, please email [ambaring@mdanderson.org](mailto:ambaring@mdanderson.org)

## MD Anderson Planning Committee

**Michael A. Davies, MD, PhD (Co-Chair)**  
*Associate Professor  
Deputy Chair  
Melanoma Medical Oncology*

**Patrick Hwu, MD (Co-Chair)**  
*Division Head  
Cancer Medicine  
Chair  
Melanoma Medical Oncology*

**Merrick I. Ross, MD (Co-Chair)**  
*Professor  
Surgical Oncology*

**Michael K. Wong, MD, PhD (Co-Chair)**  
*Professor  
Melanoma Medical Oncology*

**Allison Baring, CMP**  
*CME Conference Planner  
CME/Conference  
Management*

# CONFERENCE AGENDA

## September 28, 2018

9:00 am Registration and Continental Breakfast

### 10:00 **Welcome and Introduction**

Michael A. Davies, MD, PhD; Patrick Hwu, MD; Merrick I. Ross, MD

### **Session 1- Melanoma: Initial Diagnosis, Staging, and Surgical Management**

#### 10:05 **Introduction**

Merrick I. Ross, MD

#### 10:10 **What is New in the 8th Edition AJCC Melanoma Staging System?**

Jeffrey E. Gershenwald, MD

#### 10:35 **Melanoma Pathology and Biomarkers, 2018**

Michael Tetzlaff, MD, PhD

#### 11:00 **Melanoma Diagnosis and Screening Initiatives**

Kelly C. Nelson, MD

#### 11:30 **Surgical Management of Clinically Localized Disease**

Merrick I. Ross, MD

#### 12:00 pm **Multidisciplinary Panel & Case Discussion**

#### 12:40 **Summary**

Merrick I. Ross, MD

12:45 Lunch- Provided

### **Session 2- Integrating New Therapies in the Management of Regional Disease**

#### 1:30 **Opening Remarks**

Michael A. Davies, MD, PhD

#### 1:35 **Adjuvant Therapy: New Immune and Targeted Therapy Options**

Hussein Tawbi, MD, PhD

#### 2:05 **A New Approach: Neoadjuvant Therapy**

Rodabe N. Amaria, MD

#### 2:35 **The Role of Surgery and Intralesional Therapy for Regional Disease**

Robert H. I. Andtbacka, MD, CM

#### 3:05 **Multidisciplinary Panel & Case Discussion**

#### 3:45 **Summary**

Michael A. Davies, MD, PhD

3:50 Break

### **Session 3- New Breakthroughs in Melanoma Research**

#### 4:10 **Opening Remarks**

Patrick Hwu, MD

#### 4:15 **Personalizing Therapy for Melanoma**

Jennifer Wargo, MD

#### 4:50 **New Immunotherapies for Melanoma**

Omid Hamid, MD

#### 5:25 **Summary**

Patrick Hwu, MD

5:30 pm Adjourn and Reception

## September 29, 2018

7:00 am Registration and Continental Breakfast

### **Session 4- Metastatic Melanoma:**

#### **What's New in Immune and Targeted Therapy**

#### 8:00 **Introduction**

Patrick Hwu, MD

#### 8:05 **Understanding and Overcoming Resistance to Anti-PD1**

Patrick Hwu, MD

#### 8:35 **Recognition and Management of Autoimmune Toxicities**

Adi Diab, MD

#### 9:05 **Targeted Therapy for BRAF-Mutant Melanoma:**

##### **Which Regimen for Which Patient?**

Ryan J. Sullivan, MD

#### 9:35 **Multidisciplinary Panel & Case Discussion**

#### 10:15 **Summary**

Patrick Hwu, MD

10:20 Break

### **Session 5- The Art of Melanoma Management**

#### 10:40 **Introduction**

Michael K. Wong, MD, PhD

#### 10:45 **Beyond BRAF Inhibitors:**

##### **Emerging Targeted Therapy Agents & Strategies**

Ryan J. Sullivan, MD

#### 11:15 **CNS Metastases: The Role of Radiation and Surgery**

Jing Li, MD

#### 11:45 **CNS Metastases: The Role of Systemic Therapy**

Michael A. Davies, MD, PhD

#### 12:15 pm **The Art of Melanoma- Challenging Subtypes and Metastatic Sites**

Michael K. Wong, MD, PhD

#### 12:45 **Multidisciplinary Panel & Case Discussion**

#### 1:25 **Closing Remarks**

Michael A. Davies, MD, PhD; Patrick Hwu, MD; Merrick I. Ross, MD;

Michael K. Wong, MD, PhD

1:30 pm Adjourn

## MD Anderson Faculty

### **Rodabe N. Amaria, MD**

*Assistant Professor  
Melanoma Medical Oncology*

### **Michael A. Davies, MD, PhD (Co-Chair)**

*Associate Professor  
Deputy Chair  
Melanoma Medical Oncology*

### **Adi Diab, MD**

*Assistant Professor  
Melanoma Medical Oncology*

### **Jeffrey E. Gershenwald, MD**

*Professor  
Surgical Oncology*

### **Patrick Hwu, MD (Co-Chair)**

*Division Head  
Cancer Medicine  
Chair  
Melanoma Medical Oncology*

### **Jing Li, MD**

*Associate Professor  
Radiation Oncology*

### **Kelly C. Nelson, MD**

*Clinical Associate Professor  
Dermatology*

### **Merrick I. Ross, MD (Co-Chair)**

*Professor  
Surgical Oncology*

### **Hussein Tawbi, MD, PhD**

*Associate Professor  
Melanoma Medical Oncology  
Chair*

### **Michael Tetzlaff, MD, PhD**

*Associate Professor  
Pathology Administration*

### **Jennifer Wargo, MD**

*Associate Professor  
Surgical Oncology*

### **Michael K. Wong, MD, PhD (Co-Chair)**

*Professor  
Melanoma Medical Oncology*

## Guest Faculty

### **Robert H.I. Andtbacka, MD, CM**

*Associate Professor  
Surgical Oncology  
University of Utah School  
of Medicine  
Co-Director  
Melanoma Program &  
Melanoma Clinical Research  
Program  
Huntsman Cancer Institute  
Salt Lake City, Utah*

### **Omid Hamid, MD**

*Chief, Translational Research  
and Immunotherapy  
Director, Melanoma Therapeutics  
The Angeles Clinic and Research  
Institute  
Los Angeles, California*

### **Ryan J. Sullivan, MD**

*Assistant Professor  
Medicine  
Harvard Medical School  
Assistant Professor  
Hematology/Oncology  
Massachusetts General  
Hospital  
Boston, Massachusetts*

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

The University of Texas MD Anderson Cancer Center does not endorse the commercial products, equipment, or services presented by program supporters/exhibitors.

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.

## Registration Information

On-site registration opens at 9:00 am on Friday, September 28. Breakfast will be available. The Welcome and Introduction will begin at 10:00 am and the conference will adjourn at 1:30 pm on Saturday, September 29. Advanced registration is encouraged as space and materials are limited.

**The deadline for advanced registration is Monday, August 20, 2018.**

### **There are three ways to register:**

1. Online at: [www.mdanderson.org/conferences](http://www.mdanderson.org/conferences)
2. Fax to: 713-794-1724
3. Mail to: CME/Conference Management – Unit 1781  
The University of Texas MD Anderson Cancer Center  
P.O. Box 301407  
Houston, TX 77230-1407

### **We accept the following forms of payment:**

- Check (payable through U.S. banks only)
- Money Order
- Credit Cards (MasterCard, VISA, and American Express)
- Cash (on-site registration only)

A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee. The conference registration fee includes tuition, final conference agenda, continental breakfasts, breaks, lunch and reception. Please refer to the registration form for specific information regarding fees.

## Refund/Cancellation Policy

The registration fee, minus a \$50 administrative handling fee, is refundable if a written request is received on or before **August 20, 2018**. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or the contact numbers as given on the registration form. In case of activity cancellation, liability of the Department of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee.

The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

For additional information, please contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866.

## Special Assistance

Contact the Department of CME/Conference Management at 713-792-2223 or toll-free at 866-849-5866 if you have any special dietary or ADA accommodation needs.

## Accommodations

- A block of rooms has been reserved for conference attendees at the **Houston Marriott Medical Center** located at 6580 Fannin Street, Houston, Texas.
- Early hotel reservation is suggested and the room block cutoff date is: **Thursday, September 6, 2018.**
- The hotel phone number is 1-800-228-9290.
- When you make reservations, be sure to mention the group name: **MD Anderson Melanoma Meeting** room block to be assured of receiving the special meeting rate of \$205 for a standard guest room. Please add 17% Texas state and local taxes.

## Ground Transportation

*(prices are subject to change and variable depending on location of conference)*

- Houston is served by two airports, George Bush Intercontinental (IAH) and William P. Hobby (HOU).
- Taxicabs are available at an estimated cost for \$50-60, to or from William P. Hobby Airport or George Bush Intercontinental Airport.
- Super Shuttle operates a shuttle bus between George Bush Intercontinental Airport and the Houston Marriott Medical Center for \$27 one-way and \$54 round-trip. For more information, call 713-523-8888 or toll-free at 800-258-3826 or online at www.supershuttle.com.
- Super Shuttle operates a shuttle bus between William P. Hobby Airport and the Houston Marriott at the Texas Medical Center for \$24 one-way and \$48 round-trip. For more information, call 713-523-8888 or toll-free at 800-258-3826 or online at www.supershuttle.com.

### CONFERENCE REGISTRATION - 176700/30/120686/41 The Art and Science of Managing the New Melanoma Landscape – 5th Annual Collaborative Conference — September 28-29, 2018

Last Name		First	MI	Highest Degree
Department (include unit no.)			Specialty	
Institution				
MD Anderson Employee ID No. (required for all MDACC employees):				
Physician <input type="checkbox"/> Yes <input type="checkbox"/> No				
Street				
City				
Daytime Phone (with area code)		State/Foreign Country/Zip or Mail Code		
Cell Phone (with area code)		Fax (with area code)		
E-mail Address (please print)				
Emergency Contact				
Phone (with area code)				
Credit Card Holder Name (First/Last)				
Charge the following: <input type="checkbox"/> VISA <input type="checkbox"/> MC <input type="checkbox"/> AMEX				
Credit Card Number				
Expiration Date				
Security Code/CVV/CSV				
Credit Card Holder Billing Address & ZIP Code				
<b>MD Anderson Interdepartmental Transfer (IDT) No.: *Fund Group 90 will not be accepted</b>				
Business Unit		Department		Fund
Fund Group*		Fund		Fund Type
Authorized Signature <b>REQUIRED</b> for CREDIT CARD or IDT				
IDT Approver Name (First/Last) please print				

THIS IS NOT A SELF-MAILER - Address to:  
**The Art and Science of Managing the  
 New Melanoma Landscape-  
 5th Annual Collaborative Conference**  
 Department of CME/Conference Management – Unit 1781  
 The University of Texas MD Anderson Cancer Center  
 PO Box 301407, Houston, TX 77230-1407  
 or fax to 713-794-1724

Make check or money order payable to:  
**The University of Texas MD Anderson Cancer Center**

### Registration Fees

#### Physicians (MDs/DOs)

- Postmarked before August 20 .....\$150
- Postmarked after August 20.....\$200

#### RNs/NPs/PAs/Trainees

- Postmarked before August 20 .....\$100
- Postmarked after August 20.....\$125

### MD Anderson Registration Fees

#### Physicians (MDs/DOs)

- Postmarked before August 20 .....\$50
- Postmarked after August 20.....\$75

**RNs/NPs/PAs/Trainees..... Complimentary**

**Will you be attending the Friday evening reception at the Marriott?.....**  Yes  No

Department of CME/Conference Management- Unit 1781  
The University of Texas MD Anderson Cancer Center  
176700/30/120686/41  
PO Box 301407  
Houston, TX 77230-1407

---

Non-Profit Org.  
U.S. Postage  
PAID  
Houston, TX  
Permit No. 7052